Company intelligence / Profile preview

Suzhou Auzone Biological Technology

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Auzone has submitted an NDA to the US FDA for edaravone oral tablets (TTYP01) in amyotrophic lateral sclerosis (ALS), with expected approval in 2025. Phase 3 for acute ischemic stroke is completed in China. Phase 2 for autism spectrum disorder is ongoing. Early phase work for Alzheimer's and acute mountain diseases is planned or upcoming.[7][8]

Therapeutic areas: PsychiatryNeurologyCardiovascularPulmonology
Modalities: Small moleculeGene therapyFc fusion proteinAAV based gene therapy
Industry: Biotech

Partnerships

Huadong Medicine (exclusive licensing for the development, registration, production and commercialization of TTYP01 in China)[4][8]

Beyond the preview

Go deeper on Suzhou Auzone Biological Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Auzone Biological Technology.

Explore the full profile